How I treat EBV lymphoproliferation
Top Cited Papers
Open Access
- 5 November 2009
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 114 (19) , 4002-4008
- https://doi.org/10.1182/blood-2009-07-143545
Abstract
Epstein-Barr virus (EBV)–associated B-cell lymphoproliferation is a life-threatening complication after hematopoietic stem cell or solid organ transplantation resulting from outgrowth of EBV-infected B cells that would normally be controlled by EBV-cytotoxic T cells. During the past decade, early detection strategies, such as serial measurement of EBV-DNA load in peripheral blood samples, have helped to identify high-risk patients and to diagnose early lymphoproliferation. Treatment options include manipulation of the balance between outgrowing EBV-infected B cells and the EBV cytotoxic T lymphocyte response and targeting the B cells with monoclonal antibodies or chemotherapy. Major challenges remain for defining indications for preemptive therapies and integrating novel and conventional therapies.Keywords
This publication has 72 references indexed in Scilit:
- Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantationBlood, 2007
- Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trialBlood, 2007
- A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus–associated lymphoid malignanciesBlood, 2006
- Treatment of solid organ transplant recipients with autologous Epstein Barr virus–specific cytotoxic T lymphocytes (CTLs)Blood, 2006
- Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantationBlood, 2006
- Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantationCancer, 2005
- Impaired recovery of Epstein-Barr virus (EBV)—specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative diseaseBlood, 2003
- Epstein–Barr Virus InfectionNew England Journal of Medicine, 2000
- Donor T Cells to Treat EBV-Associated LymphomaNew England Journal of Medicine, 1994
- Stable replication of plasmids derived from Epstein–Barr virus in various mammalian cellsNature, 1985